Clinical Trial Search

Primary: Duration of Continuous Therapy — 18.3; 16 Hours

Primary: Number of Participants With 1 or More Severe Asthma Exacerbations — 186; 154 participants — p=0.036

Primary: Length of Stay — 2.9; 2.9 days — p=0.632

Primary: Proportion of Participants With Severe Asthma Exacerbations — 0.52; 0.55 proportion of participants

Primary: Hospital Admission — 57; 208 Participants

Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2

Primary: Percentage of Patients With Suspected Adverse Drug Reactions (ADRs) — 5.59 Percentage of participants

Primary: Reduction in Rate of Asthma Exacerbations — 0.74; 0.47; 0.58; 0.42 Number of asthma exacerbations per year — p=0.0049

Primary: Patients Hospitalization Rate — 82; 75 participants

Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510

Primary: Change in Percent of Predicted Peak Expiratory Flow Rate (PEFR) at t15 — 59.56; 52.45 percentage of predicted

Primary: Change in Overall Asthma Symptoms From Baseline — -0.60; -0.15; -0.88; -0.48 units on a scale

Primary: Change in Pulmonary Asthma Score (PAS) — 0.9; 0.4 mean PAS score

Primary: The Time-weighted Average of Change in Forced Expiratory Volume in One Second (FEV1) — 0.09; 0.17; 0.01 Liter — p=0.022

Primary: Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness (GETE) — 190; 29; 187; 28 participants

Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8

Primary: Baseline-adjusted FEV1 30 Minutes After Each Cumulative Dose — 0.421; 0.488; 0.548; 0.586 Liter

Primary: Change in Asthma Control Questionnaire (ACQ) Score — 0.52 score on a scale

Primary: Time to First Severe Exacerbation — 43.75; 49.43 Days — p=0.758

Primary: Percentage of Participants With First Clinically Significant Exacerbation in Part C — 31.8; 20.2; 49.3; 32.3 Percentage of participants — p=0.004

Primary: Change in Composite Asthma Severity Index (CASI) — 5; 5; 5 score on a scale — p=0.52

Primary: Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F…

Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53

Primary: Change in Forced Expiratory Volume in One Second (FEV1) % — 3.6; 5 Percentage of FEV1

Primary: Respiratory Adverse Events Per Subject — 9.1; 3.4; 2.6; 2.2 Respiratory Adverse Events/Subject

Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage

Primary: Number of Participants With Suspected Adverse Drug Reactions (ADRs) — 5 Participants

Primary: %FEV1 — 20; 34; 26; 31 %-predicted

Primary: Difference in ASM Mass Between Groups

Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) — 0.294; 0.284; 0.308; 0.240 Liter